Pink Sheet recently featured an interview with Cereno Scientific's CEO, Sten Sorensen, on the benefits of leveraging existing safety data from its broader HDAC platform to streamline the development of its pulmonary hypertension drug, CS014. As the journalst, Aakash Babu states, for cash‑strapped biotechs, this model offers a blueprint for capital‑efficient development.

Read the article here.